Targeting B Cells to Modify MS, NMOSD, and MOGAD Part 1

被引：56

作者：

Graf, Jonas ^{[1
]}

Mares, Jan ^{[2
]}

Barnett, Michael ^{[3
]}

Aktas, Orhan ^{[1
]}

Albrecht, Philipp ^{[1
]}

Zamvil, Scott S. ^{[4
]}

Hartung, Hans-Peter ^{[1
,3
]}

机构：

[1] Heinrich Heine Univ, Med Fac, Dept Neurol, Univ Hosp, Dusseldorf, Germany

[2] Palacky Univ, Dept Neurol, Olomouc, Czech Republic

[3] Univ Sydney, Brain & Mind Ctr, Dept Neurol, Sydney, NSW, Australia

[4] Univ Calif San Francisco, UCSF Weill Inst Neurosci, Dept Neurol, San Francisco, CA 94143 USA

来源：

NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION | 2021年 / 8卷 / 01期

关键词：

D O I：

10.1212/NXI.0000000000000918

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Ocrelizumab, rituximab, ofatumumab, ublituximab, inebilizumab, and evobrutinib are immunotherapies that target various B cell-related proteins. Most of these treatments have proven efficacy in relapsing and progressive forms of MS and neuromyelitis optica spectrum disease (NMOSD), or are in advanced stages of clinical development. Currently, ocrelizumab, ofatumumab, and inebilizumab are licensed for treatment of MS and NMOSD, respectively. This review focuses on the current state of knowledge about the role of B lymphocytes in immune-mediated pathophysiology and its implications for the mode of action. To understand the significance of this breakthrough in the context of the current MS therapeutic armamentarium, this review more closely examines the clinical development of CD20 depletion and the pioneering contribution of rituximab. Phase 3 and the recently published postmarketing studies will be highlighted to better understand the relevant efficacy data and safety aspects of long-term B-cell depletion.

引用

页数：11

共 60 条

[21] Treatment of Neuromyelitis Optica With Rituximab Retrospective Analysis of 25 Patients [J].

Jacob, Anu ;

Weinshenker, Brian G. ;

Violich, Ivo ;

McLinskey, Nancy ;

Krupp, Lauren ;

Fox, Robert J. ;

Wingerchuk, Dean M. ;

Boggild, Mike ;

Constantinescu, Cris S. ;

Miller, Aaron ;

De Angelis, Tracy ;

Matiello, Marcelo ;

Cree, Bruce A. C. .

ARCHIVES OF NEUROLOGY, 2008, 65 (11) :1443-1448

[22] MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome [J].

Jarius, Sven ;

Ruprecht, Klemens ;

Kleiter, Ingo ;

Borisow, Nadja ;

Asgari, Nasrin ;

Pitarokoili, Kalliopi ;

Pache, Florence ;

Stich, Oliver ;

Beume, Lena-Alexandra ;

Huemmert, Martin W. ;

Ringelstein, Marius ;

Trebst, Corinna ;

Winkelmann, Alexander ;

Schwarz, Alexander ;

Buttmann, Mathias ;

Zimmermann, Hanna ;

Kuchling, Joseph ;

Franciotta, Diego ;

Capobianco, Marco ;

Siebert, Eberhard ;

Lukas, Carsten ;

Korporal-Kuhnke, Mirjam ;

Haas, Juergen ;

Fechner, Kai ;

Brandt, Alexander U. ;

Schanda, Kathrin ;

Aktas, Orhan ;

Paul, Friedemann ;

Reindl, Markus ;

Wildemann, Brigitte .

JOURNAL OF NEUROINFLAMMATION, 2016, 13

[23] Clinical presentation and prognosis in MOG-antibody disease: a UK study [J].

Jurynczyk, Maciej ;

Messina, Silvia ;

Woodhall, Mark R. ;

Raza, Naheed ;

Everett, Rosie ;

Roca-Fernandez, Adriana ;

Tackley, George ;

Hamid, Shahd ;

Sheard, Angela ;

Reynolds, Gavin ;

Chandratre, Saleel ;

Hemingway, Cheryl ;

Jacob, Anu ;

Vincent, Angela ;

Leite, M. Isabel ;

Waters, Patrick ;

Palace, Jacqueline .

BRAIN, 2017, 140 :3128-3138

[24] Neurodegeneration in multiple sclerosis and neuromyelitis optica [J].

Kawachi, Izumi ;

Lassmann, Hans .

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2017, 88 (02) :137-145

[25] Individualized B cell-targeting therapy for neuromyelitis optica spectrum disorder [J].

Kim, Su-Hyun ;

Hyun, Jae-Won ;

Kim, Ho Jin .

NEUROCHEMISTRY INTERNATIONAL, 2019, 130

[26] B Cell-Directed Therapeutics in Multiple Sclerosis: Rationale and Clinical Evidence [J].

Kinzel, Silke ;

Weber, Martin S. .

CNS DRUGS, 2016, 30 (12) :1137-1148

[27] Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties [J].

Klein, Christian ;

Lammens, Alfred ;

Schaefer, Wolfgang ;

Georges, Guy ;

Schwaiger, Manfred ;

Moessner, Ekkehard ;

Hopfner, Karl-Peter ;

Umana, Pablo ;

Niederfellner, Gerhard .

MABS, 2013, 5 (01) :22-33

[28] Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis [J].

Komori, Mika ;

Lin, Yen Chih ;

Cortese, Irene ;

Blake, Andrew ;

Ohayon, Joan ;

Cherup, Jamie ;

Maric, Dragan ;

Kosa, Peter ;

Wu, Tianxia ;

Bielekova, Bibiana .

ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY, 2016, 3 (03) :166-179

[29] Binding mechanisms of therapeutic antibodies to human CD20 [J].

Kumar, Anand ;

Planchais, Cyril ;

Fronzes, Remi ;

Mouquet, Hugo ;

Reyes, Nicolas .

SCIENCE, 2020, 369 (6505) :793-+

[30] Rituximab induces clinical stabilization in a patient with fulminant multiple sclerosis not responding to natalizurnab Evidence for disease heterogeneity [J].

Leussink, Verena I. ;

Lehmann, Helmar C. ;

Hoerste, Gerd Meyer zu ;

Hartung, Hans-Peter ;

Stueve, Olaf ;

Kieseier, Bernd C. .

JOURNAL OF NEUROLOGY, 2008, 255 (09) :1436-1438

← 1 2 3 4 5 6 →